Avacopan is a C5aR antagonist that was approved in 2021 in the United States for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [124]. Here, C5AR1 is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.